Yago Garitaonaindia: Acquired Resistance to Immune Checkpoint Inhibitors Across Tumor Types

Yago Garitaonaindia, Translational Research Fellow at CCIT-DK – National Center for Cancer Immune Therapy of Denmark, shared a post on X:

“Our new paper in JNCCN: acquired resistance to immunotherapy (ARI) across 11 tumor types

Reconstructed IPD: 15,199 pts / 41 phase 3 trials

73.5% develop ARI by 3y
Higher CR/PR – less ARI, regardless of tumor type ARI may be determined by response depth, not histology

Cheers to Marco Donia and CCIT dk.”

Title: Acquired Resistance to Immune Checkpoint Inhibitors Across Tumor Types: A Reconstructed Individual Patient Data Analysis

Authors: Yago Garitaonaindia, Rikke Andersen, Mario Presti, Marco Donia.

Read the full article on JNCCN.

Yago Garitaonaindia: Acquired Resistance to Immune Checkpoint Inhibitors Across Tumor Types

Other articles about Immunotherapy on OncoDaily.